Exhibit 13

Meridian Bioscience, Inc. and Subsidiaries

Selected Financial Data

Income Statement Information (Amounts in thousands, except per share data)

	FY 2011		FY 2010		FY 2009		FY 2008		FY 2007
Net sales	$	159,723	$	143,000	$	148,274	$	139,639	$	122,963
Gross profit		99,298		88,696		92,442		86,480		74,940
Operating income		40,033		41,138		48,779		44,350		35,030
Net earnings		26,831		26,647		32,759		30,202		26,721
Basic earnings per share	$	0.66	$	0.66	$	0.81	$	0.75	$	0.67
Diluted earnings per share	$	0.65	$	0.65	$	0.80	$	0.74	$	0.66
Cash dividends declared per share	$	0.76	$	0.74	$	0.65	$	0.53	$	0.40
Book value per share	$	3.36	$	3.38	$	3.40	$	3.19	$	2.83

Balance Sheet Information

	FY 2011		FY 2010(1)		FY 2009		FY 2008		FY 2007
Current assets	$	90,354	$	95,305	$	117,147	$	99,458	$	93,745
Current liabilities		15,264		14,524		16,752		16,061		17,067
Total assets		155,493		154,641		155,997		146,431		132,698
Long-term debt obligations		—		—		—		—		—
Shareholders’ equity		138,524		137,361		137,905		128,489		112,948

(1) Adjusted to reflect finalization of Bioline Group purchase accounting and the change in accounting for illumigene^® instruments.

Forward Looking Statements

The Private Securities Litigation Reform Act of 1995 provides a safe harbor from civil litigation for forward-looking statements accompanied by meaningful cautionary statements. Except for historical information, this report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, which may be identified by words such as “estimates”, “anticipates”, “projects”, “plans”, “seeks”, “may”, “will”, “expects”, “intends”, “believes”, “should” and similar expressions or the negative versions thereof and which also may be identified by their context. Such statements, whether expressed or implied, are based upon current expectations of the Company and speak only as of the date made. The Company assumes no obligation to publicly update or revise any forward-looking statements even if experience or future changes make it clear that any projected results expressed or implied therein will not be realized. These statements are subject to various risks, uncertainties and other factors that could cause actual results to differ materially, including, without limitation, the following:

Meridian’s continued growth depends, in part, on its ability to introduce into the marketplace enhancements of existing products or new products that incorporate technological advances, meet customer requirements and respond to products developed by Meridian’s competition. While Meridian has introduced a number of internally developed products, there can be no assurance that it will be successful in the future in introducing such products on a timely basis. Meridian relies on proprietary, patented and liscensed technologies, and the Company’s ability to protect its intellectual property rights, as well as the potential for intellectual property litigation, would impact its results. Ongoing consolidations of reference laboratories and formation of multi-hospital alliances may cause adverse changes to pricing and distribution. Recessionary pressures on the economy and the markets in which our customers operate, as well as adverse trends in buying patterns from customers can change expected results. Costs and difficulties in complying with laws and regulations, including those administered by the United States Food and Drug Administration, can result in unanticipated expenses and delays and interruptions to the sale of new and existing products. The international scope of Meridian’s operations, including changes in the relative strength or weakness of the U.S. dollar, can make results difficult to predict. One of Meridian’s main growth strategies is the acquisition of companies and product lines. There can be no assurance that additional acquisitions will be consummated or that, if consummated, will be successful and the acquired businesses will be successfully integrated into Meridian’s operations. There may be risks that acquisitions may disrupt operations and may pose potential difficulties in employee retention and there may be additional risks with respect to Meridian’s ability to recognize the benefits of acquisitions, including potential synergies and cost savings or the failure of acquisitions to achieve their plans and objectives. The Company cannot predict the possible impact of recently-enacted United States healthcare legislation and any similar initiatives in other countries on its results of operations. In addition to the factors described in this paragraph, Part I, Item 1A Risk Factors of our Form 10-K contains a list and description of uncertainties, risks and other matters that may affect the Company.

CORPORATE PROFILE

Meridian is a fully integrated life science company that manufactures, markets and distributes a broad range of innovative diagnostic test kits, purified reagents and related products and offers biopharmaceutical enabling technologies. Utilizing a variety of methods, these products and diagnostic tests provide accuracy, simplicity and speed in the early diagnosis and treatment of common medical conditions, such as gastrointestinal, viral and respiratory infections. Meridian’s diagnostic products are used outside of the human body and require little or no special equipment. The Company’s products are designed to enhance patient well-being while reducing the total outcome costs of healthcare. Meridian has strong market positions in the areas of gastrointestinal and upper respiratory infections, serology, parasitology and fungal disease diagnosis. In addition, Meridian is a supplier of rare reagents, specialty biologicals and related technologies used by biopharmaceutical companies engaged in research for new drugs and vaccines. The Company markets its products and technologies to hospitals, reference laboratories, research centers, veterinary testing centers, diagnostics manufacturers and biotech companies in more than 60 countries around the world. The Company’s shares are traded through NASDAQ’s Global Select Market, symbol VIVO. Meridian’s website address is www.meridianbioscience.com.

MERIDIAN BIOSCIENCE, INC. 1

Meridian Bioscience, Inc. and Subsidiaries

Corporate Data

Corporate Headquarters
3471 River Hills Drive
Cincinnati, Ohio 45244
(513) 271-3700

Legal Counsel
Keating Muething & Klekamp PLL
Cincinnati, Ohio

Independent Public Accountants
Grant Thornton LLP
Cincinnati, Ohio

Transfer Agent, Registrar and Dividend
Reinvestment Administration

Shareholders requiring a change of name, address or ownership of stock, as well as information about shareholder records, lost or stolen certificates, dividend checks, dividend direct deposit, and dividend reinvestment should contact: Computershare Trust Company, P. O. Box 43078, Providence, RI 02940-3078; (888) 294-8217 or (781) 575-3120 (International holders only): e-mail: web.queries@computershare.com; or submit your inquiries online through www.computershare.com/contactus.

Annual Meeting

The annual meeting of the shareholders will be held on Wednesday, January 25, 2012 at 2:00 p.m. Eastern Time at the Holiday Inn Eastgate, 4501 Eastgate Boulevard, Cincinnati, OH 45245. Directions to the Holiday Inn Eastgate can be found on our website: www.meridianbioscience.com.

Common Stock Information

NASDAQ Global Select Market Symbol: “VIVO.” Approximate number of beneficial holders: 18,100. Approximate number of record holders: 1,000.

The following table sets forth by calendar quarter the high and low sales prices of the Common Stock on the NASDAQ Global Select Market.

Years Ended September 30,	2011				2010
Quarter ended:	High		Low		High		Low
December 31		24.440		21.000		24.970		19.960
March 31		24.000		20.050		23.930		19.440
June 30		24.990		22.180		20.510		16.030
September 30		27.370		15.710		21.980		16.590

Directors and Officers

Directors		Officers and Executives
William J. Motto	David C. Phillips	William J. Motto	Marco G. Calzavara
Executive Chairman of	Co-founder,	Executive Chairman of	President and
the Board	Cincinnati Works, Inc.	the Board	Managing Director,
			Meridian Bioscience Europe
John A. Kraeutler	James M. Anderson	John A. Kraeutler
Chief Executive Officer	Retired President and Chief Executive	Chief Executive Officer	Susan D. Rolih Senior Vice President,
Gary P. Kreider	Officer, Cincinnati	Richard L. Eberly	Regulatory Affairs and
Retired Partner, Keating Muething & Klekamp PLL	Children’s Hospital Medical Center	Executive Vice President, Chief Commercial Officer	Quality Assurance
			Vecheslav A. Elagin
		Lawrence J. Baldini	Senior Vice President,
Robert J. Ready		Executive Vice President,	Research and Development
Chairman of the Board and CEO, LSI Industries Inc.		Operations and Information Systems
			Marviette D. Johnson Vice President,
		Melissa A. Lueke	Human Resources
		Executive Vice President, Chief Financial Officer and Secretary

PERFORMANCE GRAPH

The following graph shows the yearly percentage change in Meridian’s cumulative total shareholder return on its Common Stock as measured by dividing the sum of (A) the cumulative amount of dividends, assuming dividend reinvestment during the periods presented and (B) the difference between Meridian’s share price at the end and the beginning of the periods presented; by the share price at the beginning of the periods presented with the Wilshire 5000 Equity Index and a Peer Group Index. The Peer Group consists of Alere Inc., Biomerica, Inc., IDEXX Laboratories, Inc., Life Technologies Corporation, Neogen Corporation, Orasure Technologies Inc., Quidel Corporation, Strategic Diagnostics Inc. and Trinity Biotech Plc.

COMPARISON OF 5 YEAR CUMULATIVE TOTAL RETURN*
Among Meridian Bioscience, Inc., the Wilshire 5000 Index
and a Peer Group

*	$100 invested on 9/30/06 in stock or index, including reinvestment of dividends.
	Fiscal year ending September 30.